Cencora Misses Q2 Forecasts, Lowers Growth Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy COR?
Source: seekingalpha
- Performance Decline: Cencora (COR) reported $78.4 billion in revenue for Q2 and adjusted EPS of $4.75, achieving approximately 4% and 8% year-over-year growth, respectively, but fell short of Wall Street forecasts, resulting in a 52-week low for its shares.
- Buyback Announcement: The company plans to repurchase $1 billion worth of stock by the end of 2026 and has raised its adjusted EPS outlook to $17.65-$17.90, indicating confidence in future profitability despite current challenges.
- Growth Outlook Downgrade: While the adjusted EPS forecast has improved, Cencora has lowered its full-year revenue growth outlook from 7%-9% to 4%-6%, reflecting the challenges in the market environment.
- Industry Impact: Cencora's disappointing results have negatively affected the stock prices of peers, including McKesson (MCK) and Cardinal Health (CAH), highlighting the widespread pressures facing the healthcare distribution sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COR
Wall Street analysts forecast COR stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 255.660
Low
400.00
Averages
415.38
High
440.00
Current: 255.660
Low
400.00
Averages
415.38
High
440.00
About COR
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Surge as Tech Stocks Lead Gains
- Tech Stocks Rally: The Nasdaq 100 surged 2.08% to reach an all-time high on Wednesday, driven by stellar earnings from chipmakers and AI infrastructure firms, particularly Advanced Micro Devices, which rose over 17% as it raised its full-year sales forecast, reflecting strong investor optimism about ongoing AI investments.
- Crude Oil Plunge: WTI crude oil prices fell more than 7% to a two-week low as market expectations for a US-Iran peace agreement increased, easing inflation fears and contributing to stock market gains, with the 10-year Treasury yield dropping to a one-week low of 4.33%.
- Employment Data Impact: The April ADP employment report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, believing it will help maintain a low interest rate environment.
- International Market Surge: Overseas stock markets closed sharply higher, with the Euro Stoxx 50 rising 2.68% and China's Shanghai Composite gaining 1.17%, indicating a positive global market response to the US economic recovery, further boosting investor confidence.
See More
Cencora Reports Q2 2026 Earnings Highlights
- Revenue Growth and Adjusted EPS: Cencora reported an adjusted EPS of $4.75 for Q2, reflecting a 7.5% growth, indicating solid operating income growth in both U.S. and International Healthcare Solutions segments, showcasing the company's robust market performance.
- Full-Year Guidance Raised: Management raised the full-year EPS guidance to a range of $17.65 to $17.90, demonstrating confidence in future profitability, despite lowering revenue growth expectations from 7%-9% to 4%-6%, primarily due to faster brand conversion rates.
- Cash Flow and Shareholder Returns: Cencora ended March with $2.2 billion in cash and plans to repurchase $1 billion worth of shares by year-end, a move aimed at enhancing shareholder returns and optimizing capital structure.
- Market Challenges and Strategic Responses: Despite challenges from manufacturer price reductions and customer concentration changes, management remains confident in maintaining operating income growth and emphasizes addressing market dynamics through digital transformation and portfolio optimization.
See More
Significant Stock Price Movements for Multiple Companies
- Arm Holdings Surge: Ahead of its earnings report, Arm Holdings saw a nearly 13% jump on Nasdaq, with UBS analyst raising its 12-month price target from $175 to $245, indicating strong market optimism for its growth potential.
- Healthpeak Properties Strong Performance: The healthcare REIT soared 18% after first-quarter funds from operations and revenue exceeded Wall Street expectations, raising its second-quarter FFO guidance to $1.71 to $1.75, reflecting robust business momentum.
- CDW Stock Decline: CDW shares dropped 19% after reporting disappointing operating income in Q1, with adjusted EPS of $2.28 matching consensus, yet the company reaffirmed its 2026 outlook, raising concerns about future performance.
- Aurora Innovation Partnership: Aurora Innovation's stock rose 9% following a deal to provide driverless technology to Berkshire Hathaway's McLane, which is expected to enhance its competitive edge in the long-haul trucking market.
See More
US Stocks Surge to New Highs Led by Tech Earnings
- Tech Stock Rally: The Nasdaq 100 index surged over 1.44% to reach an all-time high, driven by strong earnings from chipmakers and AI infrastructure stocks, reflecting market optimism about sustained investment growth in artificial intelligence.
- Crude Oil Plunge: WTI crude oil prices fell more than 6% to a two-week low as the US nears a peace agreement with Iran, which is expected to lift restrictions on the Strait of Hormuz, thereby reducing energy costs and enhancing profitability prospects for airlines and cruise lines.
- Employment Data Impact: The April ADP employment change report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, suggesting a lower likelihood of interest rate hikes.
- Earnings Optimism: So far, 84% of the 375 S&P 500 companies that reported earnings have exceeded expectations, with Q1 earnings projected to rise 12% year-over-year, indicating strong corporate profitability that further supports the stock market's upward trend.
See More
Cencora Misses Q2 Forecasts, Lowers Growth Outlook
- Performance Decline: Cencora (COR) reported $78.4 billion in revenue for Q2 and adjusted EPS of $4.75, achieving approximately 4% and 8% year-over-year growth, respectively, but fell short of Wall Street forecasts, resulting in a 52-week low for its shares.
- Buyback Announcement: The company plans to repurchase $1 billion worth of stock by the end of 2026 and has raised its adjusted EPS outlook to $17.65-$17.90, indicating confidence in future profitability despite current challenges.
- Growth Outlook Downgrade: While the adjusted EPS forecast has improved, Cencora has lowered its full-year revenue growth outlook from 7%-9% to 4%-6%, reflecting the challenges in the market environment.
- Industry Impact: Cencora's disappointing results have negatively affected the stock prices of peers, including McKesson (MCK) and Cardinal Health (CAH), highlighting the widespread pressures facing the healthcare distribution sector.
See More
Cencora Declares $0.60 Quarterly Dividend, Consistent with Previous Payouts
- Dividend Declaration: Cencora has declared a quarterly dividend of $0.60 per share, consistent with previous payouts, indicating the company's stable cash flow and profitability, which enhances investor confidence.
- Dividend Yield: The forward yield of 0.94% reflects the company's attractiveness in the current market environment, potentially drawing in more investors seeking stable income.
- Payment Schedule: The dividend will be payable on June 1, with a record date of May 15 and an ex-dividend date also on May 15, providing shareholders with a clear timeline that aids in financial planning.
- Future Outlook: Cencora is also set to acquire EyeSouth Partners' retina business for $1.1 billion, a move that not only expands its market share but may also enhance overall profitability through business integration.
See More
US Stocks Surge as Tech Stocks Lead Gains
- Tech Stocks Rally: The Nasdaq 100 surged 2.08% to reach an all-time high on Wednesday, driven by stellar earnings from chipmakers and AI infrastructure firms, particularly Advanced Micro Devices, which rose over 17% as it raised its full-year sales forecast, reflecting strong investor optimism about ongoing AI investments.
- Crude Oil Plunge: WTI crude oil prices fell more than 7% to a two-week low as market expectations for a US-Iran peace agreement increased, easing inflation fears and contributing to stock market gains, with the 10-year Treasury yield dropping to a one-week low of 4.33%.
- Employment Data Impact: The April ADP employment report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, believing it will help maintain a low interest rate environment.
- International Market Surge: Overseas stock markets closed sharply higher, with the Euro Stoxx 50 rising 2.68% and China's Shanghai Composite gaining 1.17%, indicating a positive global market response to the US economic recovery, further boosting investor confidence.
See More
Cencora Reports Q2 2026 Earnings Highlights
- Revenue Growth and Adjusted EPS: Cencora reported an adjusted EPS of $4.75 for Q2, reflecting a 7.5% growth, indicating solid operating income growth in both U.S. and International Healthcare Solutions segments, showcasing the company's robust market performance.
- Full-Year Guidance Raised: Management raised the full-year EPS guidance to a range of $17.65 to $17.90, demonstrating confidence in future profitability, despite lowering revenue growth expectations from 7%-9% to 4%-6%, primarily due to faster brand conversion rates.
- Cash Flow and Shareholder Returns: Cencora ended March with $2.2 billion in cash and plans to repurchase $1 billion worth of shares by year-end, a move aimed at enhancing shareholder returns and optimizing capital structure.
- Market Challenges and Strategic Responses: Despite challenges from manufacturer price reductions and customer concentration changes, management remains confident in maintaining operating income growth and emphasizes addressing market dynamics through digital transformation and portfolio optimization.
See More
Significant Stock Price Movements for Multiple Companies
- Arm Holdings Surge: Ahead of its earnings report, Arm Holdings saw a nearly 13% jump on Nasdaq, with UBS analyst raising its 12-month price target from $175 to $245, indicating strong market optimism for its growth potential.
- Healthpeak Properties Strong Performance: The healthcare REIT soared 18% after first-quarter funds from operations and revenue exceeded Wall Street expectations, raising its second-quarter FFO guidance to $1.71 to $1.75, reflecting robust business momentum.
- CDW Stock Decline: CDW shares dropped 19% after reporting disappointing operating income in Q1, with adjusted EPS of $2.28 matching consensus, yet the company reaffirmed its 2026 outlook, raising concerns about future performance.
- Aurora Innovation Partnership: Aurora Innovation's stock rose 9% following a deal to provide driverless technology to Berkshire Hathaway's McLane, which is expected to enhance its competitive edge in the long-haul trucking market.
See More
US Stocks Surge to New Highs Led by Tech Earnings
- Tech Stock Rally: The Nasdaq 100 index surged over 1.44% to reach an all-time high, driven by strong earnings from chipmakers and AI infrastructure stocks, reflecting market optimism about sustained investment growth in artificial intelligence.
- Crude Oil Plunge: WTI crude oil prices fell more than 6% to a two-week low as the US nears a peace agreement with Iran, which is expected to lift restrictions on the Strait of Hormuz, thereby reducing energy costs and enhancing profitability prospects for airlines and cruise lines.
- Employment Data Impact: The April ADP employment change report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, suggesting a lower likelihood of interest rate hikes.
- Earnings Optimism: So far, 84% of the 375 S&P 500 companies that reported earnings have exceeded expectations, with Q1 earnings projected to rise 12% year-over-year, indicating strong corporate profitability that further supports the stock market's upward trend.
See More
Cencora Misses Q2 Forecasts, Lowers Growth Outlook
- Performance Decline: Cencora (COR) reported $78.4 billion in revenue for Q2 and adjusted EPS of $4.75, achieving approximately 4% and 8% year-over-year growth, respectively, but fell short of Wall Street forecasts, resulting in a 52-week low for its shares.
- Buyback Announcement: The company plans to repurchase $1 billion worth of stock by the end of 2026 and has raised its adjusted EPS outlook to $17.65-$17.90, indicating confidence in future profitability despite current challenges.
- Growth Outlook Downgrade: While the adjusted EPS forecast has improved, Cencora has lowered its full-year revenue growth outlook from 7%-9% to 4%-6%, reflecting the challenges in the market environment.
- Industry Impact: Cencora's disappointing results have negatively affected the stock prices of peers, including McKesson (MCK) and Cardinal Health (CAH), highlighting the widespread pressures facing the healthcare distribution sector.
See More
Cencora Declares $0.60 Quarterly Dividend, Consistent with Previous Payouts
- Dividend Declaration: Cencora has declared a quarterly dividend of $0.60 per share, consistent with previous payouts, indicating the company's stable cash flow and profitability, which enhances investor confidence.
- Dividend Yield: The forward yield of 0.94% reflects the company's attractiveness in the current market environment, potentially drawing in more investors seeking stable income.
- Payment Schedule: The dividend will be payable on June 1, with a record date of May 15 and an ex-dividend date also on May 15, providing shareholders with a clear timeline that aids in financial planning.
- Future Outlook: Cencora is also set to acquire EyeSouth Partners' retina business for $1.1 billion, a move that not only expands its market share but may also enhance overall profitability through business integration.
See More
